Сравнительная эффективность современных методов терапии раннего ревматоидного артрита (предварительные результаты)

1. <div><p>Bukhari М. A., Wiles N. J., Lunt М. et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthr. Rheum. 2003, 48, 46-53.</p><p>Choy E. H., Scott D. L., Kingsley G. H. et al. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage; a randomised double blind trial of sulphasalazine versus diclofenac sodium. Clin. Exper. Rheumatol., 2002, 20, 351-358.</p><p>Lard L. R., Visser H., Speyer I. et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies. Amer. J. Med., 2001, 111, 446-51.</p><p>Peltomaa R., Paimela L., Kautiainen H. et al. Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann. Rheum. Dis., 2002, 61, 889-894.</p><p>Verstappen S. М., Jacobs J. W., Bijlsma J. W et al. Utrecht arthritis cohort study group. Five-year fol- lowup of rheumatoid arthritis patients after early treatment with disease-modifying anti-rheumatic drugs versus treatment according to the pyramid approach in the first year. Arthr. Rheum., 2003, 48, 1797-1807.</p><p>Mottonen Т., Hannonen P., Leirisalo-Repo M. et al. Comparison of combination therapy with single-drug therapy in earley rheumatoid arthritis: a randomized trial. FIN-RACo trial group. Lancet, 1999, 353, 15681573.</p><p>Nell V. P., Machold K. P., Eberl G. et al. Benefit of veiy early referral and very early therapy with disease- modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford), 2004, 43, 906-914.</p><p>Strand V, Cohen S, Schiff Metal, from the Leflunomide Rheumatoid Anhritis Investigators group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Intern. Med., 1999, 159, 2542-50.</p><p>Emery P., Breedveld F. C., Lemmel E. M. et al. A comparison of the efficacy and safety of lejluno- mide and metotrexate for the treatment of rheumatoid arthritis. Rheumatology, 2000, 39, 655-65.</p><p>Smolen J. S., Kalden J. K, Scott D. L. et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomized, multicentre trial. Lancet, 1999, 353, 259-266.</p><p>van Everdinger A. A., Jacobs J. W., van Reesema D. R., Bijlsma J. W. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann. Intern. Med., 2002, 136, 1-12.</p><p>Boers М., Verhoeven A. C., Marcusse H. M. et at. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet, 1997, 350, 309-318.</p><p>Combe B., Landewe R., Lucas C. et al. EULAR recommendations for the management of early arthritis: report of a task force of the European standing committee for international clinical studies including therapeutics. Ann. Rheum. Dis., 2007, 66, 34-45.</p><p>Балабанова P. М., Кашеваров P. Ю., Олюнин Ю. A. и др. Антидеструктивное действие лефлуномида при раннем ревматоидном артрите. Тер. архив, 2006, 6, 6-10.</p></div><br />